Publications
71
Citations
371
Est. group size
~2
Recurring co-author estimate
Active years
8
Publishing since 2019
Nerea Lopetegui-Lia's research focuses on breast cancer, particularly hormone receptor-positive and triple-negative subtypes, and how factors like BRCA gene mutations, age, and hormone receptor status affect treatment outcomes and survival. The work also examines real-world treatment patterns, socioeconomic barriers to care, and biomarkers that may predict how well patients respond to therapy. This research is largely clinical and population-based, drawing on large patient databases and cohort studies rather than laboratory experiments.
Publication output has been variable over the past decade, with an early cluster of activity in 2019-2020, a dip around 2021-2023, and a renewed increase from 2024 through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Assessing Practice Patterns of Antidepressant Medication and Tamoxifen Use Among Patients With Hormone Receptor‐Positive Breast Cancer
Cancer Reports · 2026
- Physical Diagnosis for Cost-Effective Care: The Case of Painless Zoster
The American Journal of Medicine · 2025
- Abstract P2-10-07: Practice patterns and survival analysis of early-stage HER-negative breast cancers with low and intermediate levels of hormone receptor expression: a 2018-2020 US National Cancer Database analysis
Clinical Cancer Research · 2025
- 200P Role of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among men with node-positive (pN1) hormone receptor positive (HR+) breast cancer
ESMO Open · 2025
- TREM-1 upregulation as a potential predictive immune biomarker of pathologic complete response (pCR) in patients (pts) with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (NAT).
Journal of Clinical Oncology · 2025
- Erratum: Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
JCO Oncology Practice · 2025
- Abstract P2-12-04: Impact of Weight and Weight Variation in Adolescent and Young Adult (AYA) Women with Invasive Breast Cancer
Clinical Cancer Research · 2025
- Abstract P3-10-03: Real-world first-line immunotherapy use and overall survival rates for triple-negative breast cancer: analyses from a 2018-2020 US population-based cohort
Clinical Cancer Research · 2025
- Abstract P2-02-24: Evaluating ChatGPT as an educational resource for patients with Breast cancer: A preliminary investigation
Clinical Cancer Research · 2025
- Understanding socioeconomic barriers to breast cancer treatment in the Appalachian region.
JCO Oncology Practice · 2025
- The Reply
The American Journal of Medicine · 2025
- Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Annals of Oncology · 2024
- Characterization of HER2‐low breast cancer in young women with germline <i>BRCA1/2</i> pathogenetic variants: Results of a large international retrospective cohort study
Cancer · 2024
- Real‐world outcomes of patients with resected stage <scp>III</scp> melanoma treated with adjuvant therapies
Cancer Medicine · 2024
- Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
ESMO Open · 2024
- Journal of Clinical Oncology×13
- Cureus×9
- ESMO Open×4
- The American Journal of Medicine×4
- Clinical Cancer Research×4
- Margaret E. Gatti‐Mays
Medicine · The Ohio State University
- Asrar Alahmadi
Medicine · The Ohio State University
- Amir Yousif
Medicine · The Ohio State University
- Abdul Miah
Medicine · The Ohio State University
- Adam Khorasanchi
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile